Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO)

BACKGROUND: This study was conducted to investigate a new short-course radiotherapy regimen for patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a dominant debilitating symptom. METHODS / DESIGN: This is an international, multi-center single arm prospective feasibil...

Descripción completa

Detalles Bibliográficos
Autores principales: Carl, Jesper, Rades, Dirk, Doemer, Claudia, Setter, Cornelia, Dunst, Jürgen, Holländer, Niels Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327575/
https://www.ncbi.nlm.nih.gov/pubmed/30630502
http://dx.doi.org/10.1186/s13014-019-1209-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327575/
https://www.ncbi.nlm.nih.gov/pubmed/30630502
http://dx.doi.org/10.1186/s13014-019-1209-0

Ejemplares similares